Invention Grant
- Patent Title: STAT3 inhibitor formulation
-
Application No.: US16603110Application Date: 2018-04-05
-
Publication No.: US10913709B2Publication Date: 2021-02-09
- Inventor: Robert H. Shoemaker , Michael W. Lovell , Jonathan M. White , Shanker Gupta
- Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services , GLG Pharma, LLC , MRIGLobal
- Applicant Address: US MD Bethesda; US FL Jupiter; US MO Kansas City
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services,GLG Pharma, LLC,MRIGLobal
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services,GLG Pharma, LLC,MRIGLobal
- Current Assignee Address: US MD Bethesda; US FL Jupiter; US MO Kansas City
- Agency: Leydig, Volt & Mayer, Ltd.
- International Application: PCT/US2018/026228 WO 20180405
- International Announcement: WO2018/187551 WO 20181011
- Main IPC: C07C309/73
- IPC: C07C309/73 ; A61P35/00 ; C07C215/10 ; A61K9/00 ; A61K9/08

Abstract:
Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.
Information query